Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer
First-line ADT + ARPI was associated with significantly improved outcomes vs ADT alone in de novo mCSPC. These real-world results align with the benefits demonstrated in trials, supporting integration of TI with ARPIs into clinical practice to improve survival outcomes in patients with de novo mCSPC.
Authors
- Janet Kim
- Joshua Parrish (ORCID: https://orcid.org/0000-0003-3636-5688)
- Lin Gu (ORCID: https://orcid.org/0000-0003-4593-8572)
- Amanda M. De Hoedt (ORCID: https://orcid.org/0000-0002-3899-7702)
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- Nader N. El-Chaar
- Krishnan Ramaswamy (ORCID: https://orcid.org/0000-0003-0890-0268)
- Maelys Touya
- C.R. Evans
- Agnes Hong
- Thomas J. Polascik (ORCID: https://orcid.org/0000-0003-3666-1372)
Institutions
- Cedars-Sinai Medical Center (US)
- Duke University (US)
- Pfizer (United States) (US)
- Durham VA Health Care System (US)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1038/s41391-025-01000-8
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Pfizer
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders